Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD

Blood (2019) 134 (Supplement_1): 1040.

https://doi.org/10.1182/blood-2019-124876

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Mehmet Kemal Samur, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3138.

https://doi.org/10.1182/blood-2019-128689

Published: 2019

Journal Articles

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8 + cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2018-99-117282

Published: 2018

Journal Articles

DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Michael Topper, BS, Nidal Muvarak, PhD, Lora Stojanovic, BS, T Michael Creed, BS, MS, Soren Bentzen, PhD DMSc, Curt I. Civin, MD, Maria R. Baer, MD, Tami J Kingsbury, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2017) 130 (Supplement 1): 3347.

https://doi.org/10.1182/blood.V130.Suppl_1.3347.3347

Published: 2017

Journal Articles

A CK1δ/CK1ε-to-β-Catenin Circuit Is a Therapeutic Vulnerability for Primary and Drug Resistant Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Ariosto Siqueira Silva, PhD, Paula Oliveira, Tuan Nguyen, Allison Distler, Maria Coelho Siqueira Silva, Timothy Jacobson, Jamie Teer, PhD, Hongyue Dai, PhD, William Roush, PhD, John Cleveland, PhD, Kenneth H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 591.

https://doi.org/10.1182/blood.V130.Suppl_1.591.591

Published: 2017

Journal Articles

Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy

Astrid Rueflibrasse, PhD, Thomas Friess, PhD, Stephanie Lechner, Lisa Wellinger, Jurriaan Brouwer, William E. Pierceall, PhD

Blood (2017) 130 (Supplement 1): 2071.

https://doi.org/10.1182/blood.V130.Suppl_1.2071.2071

Published: 2017

Journal Articles

Secondary Solid Cancer Following Hematopoietic Cell Transplantation in Patients with Thalassemia Major

Alessia Pepe, MD, Antonella Meloni, PhD, Stella Santarone, Annalisa Natale, Mauro Di Ianni, MD PhD, Laura Pistoia, MD, Liana Cuccia, MD, Anna Spasiano, Roberto Lisi, Paolo Di Bartolomeo, MD

Blood (2017) 130 (Supplement 1): 3274.

https://doi.org/10.1182/blood.V130.Suppl_1.3274.3274

Published: 2017

Journal Articles

Role of p38γ - NFATc4 - IL17A Pathway As a Potential Therapeutic Target in Cutaneous T Cell Lymphoma

Xu Hannah Zhang, PhD, Vu N. Ngo, PhD, Natalie Sandoval, MSc, Qi Cui, Yanhong Shi, PhD, Jasmine M. Zain, MD, Christiane Querfeld, MD PhD, Chao Guo, Xiwei Wu, PhD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2725.

https://doi.org/10.1182/blood.V128.22.2725.2725

Published: 2016

Journal Articles

Expression of DDIT4 Is Correlated with NOTCH1 and High Molecular Risk in Acute Myeloid Leukemias

Joseph A Pinto, Leny Bravo, Luis A. Chirinos, Carlos E Vigil

Blood (2016) 128 (22): 5254.

https://doi.org/10.1182/blood.V128.22.5254.5254

Published: 2016

Journal Articles

Anti-Tumor Responses By Ibrutinib and Anti-PD-1 Blockade Is Enhanced By Phosphatidylserine-Targeting Antibody Therapy

Jian Gong, MD/PhD, Michael Gray, PhD, Jeff Hutchins, PhD, Bruce Freimark, PhD

Blood (2016) 128 (22): 5379.

https://doi.org/10.1182/blood.V128.22.5379.5379

Published: 2016

Journal Articles

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Maria Aquila Santoro, MD, Angelo Pomillo, MD, Maria Luci, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 4926.

https://doi.org/10.1182/blood.V128.22.4926.4926

Published: 2016

Journal Articles

Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances

Francesco Parlati, PhD, Shoshana Bromley-Dulfano, BS, Susan Demo, PhD, Julie Janes, MS, Matt Gross, BS, Evan Lewis, PhD, Andy MacKinnon, PhD, Mirna Rodriguez, BS, Jinfu Yang, PhD, Frances Zhao, MS, Mark Bennett, PhD

Blood (2013) 122 (21): 4226.

https://doi.org/10.1182/blood.V122.21.4226.4226

Published: 2013

Journal Articles

Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer

Rachel M Layman, MD, Amy S Ruppert, MAS, Melinda Lynn, RN, BSN, Ewa Mrozek, MD, Bhuvaneswari Ramaswamy, MD, Maryam B Lustberg, MD, Ottman Susan, RN, BSN, Sarah Carothers, MS, Eric H Kraut, MD, Charles L Shapiro, MD

Blood (2010) 116 (21): 1739.

https://doi.org/10.1182/blood.V116.21.1739.1739

Published: 2010

NARROW

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8 + cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML

A CK1δ/CK1ε-to-β-Catenin Circuit Is a Therapeutic Vulnerability for Primary and Drug Resistant Multiple Myeloma

Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy

Secondary Solid Cancer Following Hematopoietic Cell Transplantation in Patients with Thalassemia Major

Role of p38γ - NFATc4 - IL17A Pathway As a Potential Therapeutic Target in Cutaneous T Cell Lymphoma

Expression of DDIT4 Is Correlated with NOTCH1 and High Molecular Risk in Acute Myeloid Leukemias

Anti-Tumor Responses By Ibrutinib and Anti-PD-1 Blockade Is Enhanced By Phosphatidylserine-Targeting Antibody Therapy

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances

Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only